CV 205-502 treatment of macroprolactinomas

Détails

ID Serval
serval:BIB_426AF762602C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
CV 205-502 treatment of macroprolactinomas
Périodique
J Endocrinol Invest
Auteur(s)
Crottaz  B., Uske  A., Reymond  M. J., Rey  F., Siegel  R. A., Brownell  J., Gomez  F.
ISSN
0391-4097
Statut éditorial
Publié
Date de publication
10/1991
Peer-reviewed
Oui
Volume
14
Numéro
9
Pages
757-62
Notes
Research Support, Non-U.S. Gov't
Crottaz, B
Uske, A
Reymond, M J
Rey, F
Siegel, R A
Brownell, J
Gomez, F
Italy
Journal of endocrinological investigation
J Endocrinol Invest. 1991 Oct;14(9):757-62. --- Old month value: Oct
Résumé
CV 205-502, a benzoquinoline, is a new nonergot dopamine agonist compound which has been shown to be effective in lowering PRL levels in normal volunteers and in hyperprolactinemic women. Seven patients (4 men and 3 women) presenting with hyperprolactinemia due to macroprolactinoma were treated with CV 205-502 given as a single daily dose at bedtime for up to 12 months. Six patients presented with impaired gonadal function and 2 with galactorrhea. All patients but one had previously been treated with bromocriptine and 4 had undergone pituitary surgery (3 with complementary radiotherapy). Six patients responded within a few weeks to CV 205-502 treatment, PRL levels being normalized (4 patients, 0.075 to 0.150 mg/day) or significantly reduced to restore normal gonadal function (2 patients, 0.225 mg/day). The seventh patient, who had previously been resistant to bromocriptine, also failed to respond to CV 205-502 treatment even after high doses (0.450 mg/day). Under CV 205-502 treatment, follow-up with magnetic resonance imaging revealed a reduction in tumor size of up to 52% of the initial volume in the "PRL-responders" whereas an increase in tumor size was observed in the "nonresponding" patient. No biological disturbance appeared during CV 205-502 treatment and the drug tolerance was very good, with mild side-effects being reported by only 2 patients. In conclusion, CV 205-502, given once daily, appears to be a safe and effective alternative to other dopamine agonists in the treatment of macroprolactinoma, by reducing hyperprolactinemia and tumor size. It was, however, of no benefit in the one patient whose macroprolactinoma had been resistant to bromocriptine.
Mots-clé
Adult Aminoquinolines/adverse effects/*therapeutic use Bromocriptine/therapeutic use Dopamine Agents/adverse effects/*therapeutic use Drug Resistance Endocrine System Diseases/etiology Female Galactorrhea/etiology Gonads Humans Magnetic Resonance Imaging Male Middle Aged Pituitary Neoplasms/complications/*drug therapy/pathology Prolactin/blood Prolactinoma/complications/*drug therapy/pathology
Pubmed
Web of science
Création de la notice
10/04/2008 17:52
Dernière modification de la notice
03/03/2018 16:37
Données d'usage